Skip to main content

Table 3 Impact of IPO13 polymorphisms on methacholine hyperresponsiveness (PC20) in childhood asthma

From: Importin-13 genetic variation is associated with improved airway responsiveness in childhood asthma

     Treatment-stratified analysis
SNP Genic location MAF All subjects (n = 654) Budesonide (n = 214) Placebo or Nedocramil (n = 440)
rs6671164 5' genomic 0.223 0.002 - 0.004
rs4448553 5' genomic 0.223 0.02 - 0.01
rs1990150 Intron 1 0.148 0.02 - 0.04
rs2240447 Exon 2 0.224 - - -
rs2486014 Intron 2 0.097 0.04 - -
rs2301993 Intron 12 0.222 0.002 - 0.001
rs2301992 Intron 13 0.049 0.02 - 0.03
rs1636879 Intron 14 0.102 0.02 - 0.04
rs7412307 3' genomic 0.184 0.02 - 0.04
rs2428953 3' genomic 0.11 0.002 - 0.005
  1. Results based on repeated-measures analysis assuming an additive genetic model with log10-PC20. All analyses are adjusted for PC20 prior to treatment randomization, age, gender, height, study center and study visit. All-subject analysis adjusted for treatment-arm assignment (budesonide vs. other). MAF = minor allele frequency. "-" denotes nominal p-value > 0.05.